Trial Profile
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2024
Price :
$35
*
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Acronyms EPOPEX
- Sponsors DBV Technologies
- 29 Mar 2024 This trial has been completed in Ireland.
- 09 Nov 2023 According to a DBV Technologies media release, data from the study will be presented in late-breaking oral abstract presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) annual meeting on Saturday, November 11th at 9:35AM PT.
- 09 Nov 2023 Interim results published in the Media Release